Tumor associated macrophages in relapsed and refractory Hodgkin lymphoma

Leukemia Research

Volumn 37, Issue 9, 2013, Pages 1178-1183

  Casulo, Carla ^a   Arcila, Maria ^b   Bohn, Olga L ^b   Teruya Feldstein, Julie ^b   Maragulia, Jocelyn ^b   Moskowitz, Craig H ^b  

^a UNIVERSITY OF ROCHESTER MEDICAL CENTER   (United States)

^b MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

CD68; Hodgkin lymphoma; Refractory; Relapsed

Indexed keywords

BIOLOGICAL MARKER; CD68 ANTIGEN; FLUORODEOXYGLUCOSE;

ADOLESCENT; ADULT; AGED; ARTICLE; AUTOLOGOUS STEM CELL TRANSPLANTATION; CANCER PROGNOSIS; CANCER RECURRENCE; CANCER SURVIVAL; CELL COUNT; CELL INFILTRATION; CONTROLLED STUDY; EVENT FREE SURVIVAL; FEMALE; HODGKIN DISEASE; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; OVERALL SURVIVAL; POSITRON EMISSION TOMOGRAPHY; PREDICTION; PRIORITY JOURNAL; RISK ASSESSMENT; SALVAGE THERAPY; TISSUE MICROARRAY; TUMOR ASSOCIATED LEUKOCYTE; TUMOR BIOPSY;

CD68; HODGKIN LYMPHOMA; REFRACTORY; RELAPSED;

ADOLESCENT; ADULT; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; DRUG RESISTANCE, NEOPLASM; FEMALE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HODGKIN DISEASE; HUMANS; MACROPHAGES; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; SALVAGE THERAPY; SURVIVAL RATE; TRANSPLANTATION, AUTOLOGOUS; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84880961819     PISSN: 01452126     EISSN: 18735835     Source Type: Journal    
DOI: 10.1016/j.leukres.2013.03.021     Document Type: Article

References (35)

1. Ree H.J., Kadin M.E. Macrophage-histiocytes in Hodgkin's disease. The relation of peanut-agglutinin-binding macrophage-histiocytes to clinicopathologic presentation and course of disease. Cancer 1985, 56(2):333-338.
2. Coppleson L.W., Rappaport H., Strum S.B., Rose J. Analysis of the Rye classification of Hodgkin's disease. The prognostic significance of cellular composition. J Natl Cancer Inst 1973, 51(2):379-390.
3. Devilard E., Bertucci F., Trempat P., Bouabdallah R., Lorio B., Giaconia A., et al. Gene expression profiling defines molecular subtypes of classical Hodgkin's disease. Oncogene 2002, 21(19):3095-3102.
4. Chetaille B., Bertucci F., Finetti P., Esterni B., Stamatoullas A., Picquenot J.M., et al. Molecular profiling of classical Hodgkin lymphoma tissues uncovers variations in the tumor microenvironment and correlations with EBV infection and outcome. Blood 2009, 113(12):2765-3775.
5. Sanchez-Aguilera A., Montalban C., de la Cueva P., Sanchez-Verde L., Morente M.M., Garcia-Cosio M., et al. Tumor microenvironment and mitotic checkpoint are key factors in the outcome of classic Hodgkin lymphoma. Blood 2006, 108(2):662-668.
6. Steidl C., Lee T., Shah S.P., Farinha P., Han G., Nayar T., et al. Tumor-associated macrophages and survival in classic Hodgkin's lymphoma. N Engl J Med 2010, 362(10):875-885.
7. Deau B., Bachy E., Ribrag V., Delarue R., Rubio M.T., Bosq J., et al. Macrophage, mast cell and T lymphocyte infiltrations are independent predictive biomarkers of primary refractoriness or early relapse in classical Hodgkin lymphoma. Leuk Lymphoma 2013, 54(1):41-45.
8. Kuruvilla J., Keating A., Crump M. How I treat relapsed and refractory Hodgkin lymphoma. Blood 2011, 117(16):4208-4217.
9. Canellos G.P., Niedzwiecki D. Long-term follow-up of Hodgkin's disease trial. N Engl J Med 2002, 346(18):1417-1418.
10. Linch D.C., Winfield D., Goldstone A.H., Moir D., Hancock B., McMillan A., et al. Dose intensification with autologous bone-marrow transplantation in relapsed and resistant Hodgkin's disease: results of a BNLI randomised trial. Lancet 1993, 341(8852):1051-1054.
11. Schmitz N., Pfistner B., Sextro M., Sieber M., Carella A.M., Haenel M., et al. Aggressive conventional chemotherapy compared with high-dose chemotherapy with autologous haemopoietic stem-cell transplantation for relapsed chemosensitive Hodgkin's disease: a randomised trial. Lancet 2002, 359(9323):2065-2071.
12. Moskowitz C.H., Nimer S.D., Zelenetz A.D., Trippett T., Hedrick E.E., Filippa D.A., et al. A 2-step comprehensive high-dose chemoradiotherapy second-line program for relapsed and refractory Hodgkin disease: analysis by intent to treat and development of a prognostic model. Blood 2001, 97(3):616-623.
13. Moskowitz C.H., Matasar M.J., Zelenetz A.D., Nimer S.D., Gerecitano J., Hamlin P., et al. Normalization of pre-ASCT, FDG-PET imaging with second-line, non-cross resistant, chemotherapy programs improves event-free survival in patients with Hodgkin lymphoma. Blood 2012, 119(7):1665-1670.
14. Josting A., Rueffer U., Franklin J., Sieber M., Diehl V., Engert A. Prognostic factors and treatment outcome in primary progressive Hodgkin lymphoma: a report from the German Hodgkin Lymphoma Study Group. Blood 2000, 96(4):1280-1286.
15. Josting A., Franklin J., May M., Koch P., Beykirch M.K., Heinz J., et al. New prognostic score based on treatment outcome of patients with relapsed Hodgkin's lymphoma registered in the database of the German Hodgkin's lymphoma study group. J Clin Oncol 2002, 20(1):221-230. [official journal of the American Society of Clinical Oncology].
16. Farinha P., Masoudi H., Skinnider B.F., Shumansky K., Spinelli J.J., Gill K., et al. Analysis of multiple biomarkers shows that lymphoma-associated macrophage (LAM) content is an independent predictor of survival in follicular lymphoma (FL). Blood 2005, 106(6):2169-2174.
17. Tan K.L., Scott D.W., Hong F., Kahl B.S., Fisher R.I., Bartlett N.L., et al. Tumor-associated macrophages predict inferior outcomes in classic Hodgkin lymphoma: a correlative study from the E2496 intergroup trial. Blood 2012, 120(16):3280-3287.
18. Jones K., Vari F., Keane C., Crooks P., Nourse J.P., Seymour L.A., et al. Serum CD163 and TARC as disease response biomarkers in classical hodgkin lymphoma. Clin Cancer Res 2013, 19(3):731-742.
19. Barros M.H., Hassan R., Niedobitek G. Tumor-associated macrophages in pediatric classical Hodgkin lymphoma: association with Epstein-Barr virus, lymphocyte subsets, and prognostic impact. Clin Cancer Res 2012, 18(14):3762-3771.
20. Koh Y.W., Kang H.J., Park C., Yoon D.H., Kim S., Suh C., et al. The ratio of the absolute lymphocyte count to the absolute monocyte count is associated with prognosis in Hodgkin's lymphoma: correlation with tumor-associated macrophages. Oncologist 2012, 17(6):871-880.
21. Yoon D.H., Koh Y.W., Kang H.J., Kim S., Park C.S., Lee S.W., et al. CD68 and CD163 as prognostic factors for Korean patients with Hodgkin lymphoma. Eur J Haematol 2012, 88(4):292-305.
22. Jakovic L.R., Mihaljevic B.S., Perunicic Jovanovic M.D., Bogdanovic A.D., Andjelic B.M., Bumbasirevic V.Z. The prognostic relevance of tumor associated macrophages in advanced stage classical Hodgkin lymphoma. Leuk Lymphoma 2011, 52(10):1913-1919.
23. Zaki M.A., Wada N., Ikeda J., Shibayama H., Hashimoto K., Yamagami T., et al. Prognostic implication of types of tumor-associated macrophages in Hodgkin lymphoma. Virchows Arch 2011, 459(4):361-366.
24. Kamper P., Bendix K., Hamilton-Dutoit S., Honoré B., Nyengaard J.R., d'Amore F. Tumor-infiltrating macrophages correlate with adverse prognosis and Epstein-Barr virus status in classical Hodgkin's lymphoma. Haematologica 2011, 96(2):269-276.
25. Greaves P., Clear A.J., Owen D.A., Macdougall F., Wilson A., Lister A., et al. An immunohistochemical score based on CD68 and FOXP3 expression in the tumour microenvironment at diagnosis defines prognostic groups in both early and advanced stage classical Hodgkin lymphoma. Blood 2010, 116(November):750. [ASH annual meeting abstracts].
26. Deau B., Emmanuel B., Ribrag V., Delarue R., Rubio M.T., Bosque J., et al. Marophages and mast cells infiltration are biomarkers of primary refractory Hodgkin's lymphoma. Blood (ASH Annual Meeting Abstracts) 2010, 116:3881.
27. Spaepen K., Stroobants S., Dupont P., Vandenberghe P., Maertens J., Bormans G., et al. Prognostic value of pretransplantation positron emission tomography using fluorine 18-fluorodeoxyglucose in patients with aggressive lymphoma treated with high-dose chemotherapy and stem cell transplantation. Blood 2003, 102(1):53-59.
28. Svoboda J., Andreadis C., Elstrom R., Chong E.A., Downs L.H., Berkowitz A., et al. Prognostic value of FDG-PET scan imaging in lymphoma patients undergoing autologous stem cell transplantation. Bone Marrow Transplant 2006, 38(3):211-216.
29. Schot B.W., Zijlstra J.M., Sluiter W.J., van Imhoff G.W., Pruim J., Vaalburg W., et al. Early FDG-PET assessment in combination with clinical risk scores determines prognosis in recurring lymphoma. Blood 2007, 109(2):486-491.
30. Cremerius U., Fabry U., Wildberger J.E., Zimny M., Reinartz P., Nowak B., et al. Pre-transplant positron emission tomography (PET) using fluorine-18-fluoro-deoxyglucose (FDG) predicts outcome in patients treated with high-dose chemotherapy and autologous stem cell transplantation for non-Hodgkin's lymphoma. Bone Marrow Transplant 2002, 30(2):103-111.
31. Dickinson M., Hoyt R., Roberts A.W., Grigg A., Seymour J.F., Prince H.M., et al. Improved survival for relapsed diffuse large B cell lymphoma is predicted by a negative pre-transplant FDG-PET scan following salvage chemotherapy. Br J Haematol 2010, 150(1):39-45.
32. Becherer A., Mitterbauer M., Jaeger U., Kalhs P., Greinix H.T., Karanikas G., et al. Positron emission tomography with [18F]2-fluoro-D-2-deoxyglucose (FDG-PET) predicts relapse of malignant lymphoma after high-dose therapy with stem cell transplantation. Leukemia 2002, 16(2):260-267. [official journal of the Leukemia Society of America, Leukemia Research Fund, U.K].
33. Moskowitz A.J., Yahalom J., Kewalramani T., Maragulia J.C., Vanak J.M., Zelenetz A.D., et al. Pretransplantation functional imaging predicts outcome following autologous stem cell transplantation for relapsed and refractory Hodgkin lymphoma. Blood 2010, 116(23):4934-4937.
34. Moskowitz C.H., Matasar M.J., Zelenetz A.D., Nimer S.D., Gerecitano J., Hamlin P., et al. Normalization of pre-ASCT, FDG-PET imaging with second-line, non-cross-resistant, chemotherapy programs improves event-free survival in patients with Hodgkin lymphoma. Blood 2012, 119(7):1665-1670.
35. Smeltzer J.P., Cashen A.F., Zhang Q., Homb A., Dehdashti F., Abboud C.N., et al. Prognostic significance of FDG-PET in relapsed or refractory classical Hodgkin lymphoma treated with standard salvage chemotherapy and autologous stem cell transplantation. Biol Blood Marrow Transplant 2011, 17(11):1646-1652. [journal of the American Society for Blood and Marrow Transplantation].